FDG PET in lymphoma: The need for standardization of interpretation. An observer variation study

Nuclear Medicine Communications

Volumn 28, Issue 10, 2007, Pages 798-803

  Zijlstra, Josée M ^a   Comans, Emile F ^a   van Lingen, Arthur ^a   Hoekstra, Otto S ^a   Gundy, Chad M ^a   Willem Coebergh, Jan ^b   Bongers, Vivian ^b  

^a Nuclear Medicine and PET Research   (Netherlands)

^b DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Lymphoma; Observer variation; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANALYTICAL ERROR; ARTICLE; AXILLA; BONE MARROW; CLAVICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; LABORATORY DIAGNOSIS; LUNG; LYMPH NODE; LYMPH NODE METASTASIS; MEDIASTINUM; MEDICAL EXPERT; NECK; NONHODGKIN LYMPHOMA; NUCLEAR MEDICINE; OBSERVER VARIATION; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY ANALYSIS; STANDARDIZATION; TUMOR LOCALIZATION;

FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; NETHERLANDS; OBSERVER VARIATION; PHYSICIANS; POSITRON-EMISSION TOMOGRAPHY; PROFESSIONAL COMPETENCE; RADIOPHARMACEUTICALS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 34548295714     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282eff2d5     Document Type: Article

References (14)

1. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006; 47:1326-1334.
2. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91:475-481.
3. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30 (suppl 1):s82-s88.
4. Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hanel A, Bredow J, et al. Substantial impact of FDG PET imaging on therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004; 90:620-625.
5. Hoskin PJ. PET in lymphoma: what are the oncologist's needs? Eur J Nucl Med Mol Imaging 2003; 30 (suppl 1):s37-s41.
6. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, deGroot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1356-1363.
7. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91:522-529.
8. 67Ga scintigraphy as prognostic test during chemotherapy for non-hodgkin's lymphoma. Br J Haematol 2003; 123:454-462.
9. 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42:1139-1143.
10. 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 2005; 26:689-694.
11. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005; 32:749-756.
12. 18F-FDG uptake correlate with the viable cell fraction? Eur J Nucl Med Mol Imaging 2003; 30:682-688.
13. Fletcher BD, Glicksman AS, Gieser P. Interobserver variability in the detection of cervical-thoracic Hodgkin's disease by computed tomography. J Clin Oncol 1999; 17:2153-2159.
14. Robinson PJ. Radiology's Achilles' heel: error and variation in the interpretation of the Rontgen image. Br J Radiol 1997; 70:1085-1098.